Trending GLP-1 Therapies Research Papers

5 days ago • Frontiers in neuroanatomy

How GLP-1 signals in the brain's reward center may influence reward and metabolismNucleus accumbens GLP-1 signaling and its role in reward and metabolic regulation: a systematic review.

📖 Top 20% JournalSystematic Review

5 days ago • Medicine

Semaglutide’s safety and effectiveness for weight loss in obese people without diabetesEffectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.

📖 Top 50% JournalSystematic Review

6 days ago • Frontiers in endocrinology

Dietary fibers that may increase natural GLP-1 levels and feelings of fullnessDietary fibers to boost endogenous GLP-1 secretion and satiety: a scoping review.

🎖️ Top 10% JournalSystematic Review

5 days ago • Clinical pharmacology and therapeutics

Patterns of Prescriptions for Glucagon-Like Peptide-1 Drugs and Their Links to Mental Health ConditionsPrescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.

🥉 Top 5% JournalArticle

4 days ago • Frontiers in nutrition

Changes in eating experience during GLP-1 receptor agonist treatment explained by food enjoyment and desireAltered eating experience during GLP-1 receptor agonist therapy: a sensory-liking-wanting framework for food preference and nutritional behaviour.

📖 Top 20% JournalArticle

2 days ago • The Journal of the Association of Physicians of India

Real-World Experiences Using Semaglutide at a Hospital in JharkhandSemaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital.

Observational Study

6 days ago • Lancet (London, England)

Effectiveness and safety of once-daily oral zenagamtide, a new combined GLP-1 and amylin receptor drug, in adults with type 2 diabetes: a multi-center, randomized, placebo-controlled dose studyEfficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

🥇 Top 1% JournalArticle

2 days ago • Drug design, development and therapy

Side Effects Linked to Incretin-Based Diabetes Treatments: Causes, Care, and Risk ReductionAdverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation.

📖 Top 20% JournalArticle

2 days ago • Pediatric obesity

Use of Subsidized Semaglutide in Icelandic Children with Obesity in Real LifeReal-World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study.

📖 Top 20% JournalArticle

2 days ago • Annals of internal medicine

Weekly semaglutide lowers heavy drinking days after 26 weeks in people with alcohol use disorder and obesityIn alcohol use disorder and comorbid obesity, weekly semaglutide reduced heavy drinking days at 26 wk.

🥈 Top 2% JournalArticle

5 days ago • The bone & joint journal

Glucagon-like peptide-1 receptor agonists linked to better recovery within 90 days after hip and knee replacement surgeryGlucagon-like peptide-1 receptor agonists are associated with improved 90-day outcomes after total hip and knee arthroplasty : a systematic review and meta-analysis.

🥉 Top 5% JournalSystematic Review

2 days ago • Childhood obesity (Print)

Protecting Muscle and Bone Growth and Physical Abilities in Teens Taking GLP-1 TreatmentProtecting Musculoskeletal Development and Physical Function in Adolescents on GLP-1 Therapy.

📖 Top 30% JournalArticle

2 days ago • Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA

GLP-1 drugs in hip, knee, and shoulder joint replacement: links to obesity, arthritis, metabolism, and surgery risksGLP-1 receptor agonists in hip, knee and shoulder arthroplasty: Implications for obesity, osteoarthritis, metabolic optimisation and complications.

🥉 Top 5% JournalEditorial

2 days ago • Microbiology spectrum

Liraglutide's effects on changes in gut bacteriaEffects of liraglutide on gut bacterial community dynamics.

📖 Top 20% JournalArticle

4 days ago • Pediatric obesity

Liraglutide's impact on how much energy teenagers with ongoing obesity eat after stomach surgeryEffects of Liraglutide on Energy Intake in Adolescents With Persistent Obesity After Vertical Sleeve Gastrectomy.

📖 Top 20% JournalArticle

4 days ago • Biology methods & protocols

Semaglutide use linked to milder COVID-19 and flu with improved kidney health after infectionSemaglutide use linked to lower COVID-19 and influenza severity with better renal outcomes after pandemic or seasonal infection.

📖 Top 30% JournalArticle

4 days ago • Clinical nutrition ESPEN

Real-world study of how well tirzepatide works and how safe it is for people with obesityReal-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: a prospective study.

📖 Top 30% JournalArticle

1 week ago • The American journal of psychiatry

Testing Oral Semaglutide as a Treatment for Alcohol Use DisorderOral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.

🥇 Top 1% JournalArticle

6 days ago • Tobacco induced diseases

GLP-1 drugs for quitting smoking and managing weight after quitting: A review and combined analysis of clinical trialsGLP-1 agonists for smoking cessation and post-cessation weight management: A systematic review and meta-analysis of randomized trials.

📖 Top 30% JournalArticle

6 days ago • Journal of integrative neuroscience

Brain-Wide Connections of GLP1R Neurons in the Thalamic Reticular NucleusBrain-Wide Connectivity of GLP1R Neurons in the Thalamic Reticular Nucleus.

📖 Top 30% JournalArticle

6 days ago • Journal of general internal medicine

Costs and Affordability of Diabetes Drugs Like GLP-1 Agonists in the US from 2013 to 2023Spending and Affordability of Glucagon-Like Peptide-1 Receptor Agonists and Other Incretin Mimetics in the United States, 2013-2023.

🥉 Top 5% JournalArticle

6 days ago • Pharmaceutical research

Impurities and Possible Immune Reactions Linked to Generic and Mixed Versions of Glucagon-like Peptide-1 Receptor AgonistsImpurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists.

📖 Top 20% JournalArticle

5 days ago • Endocrinology, diabetes & metabolism

Tirzepatide and SGLT2 Inhibitors for Heart Failure with Normal Pumping and Obesity: Moving Toward New Treatments for Heart and Metabolic HealthTirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.

📖 Top 20% JournalArticle

4 days ago • Public health reports (Washington, D.C. : 1974)

Adults’ Ability to Use Unprescribed Semaglutide Peptide Medications CorrectlyAbility of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription.

🎖️ Top 10% JournalArticle

2 days ago • Internal medicine (Tokyo, Japan)

Unusual Anorexia Nervosa After Weight-Loss Surgery and Diabetes Medication in a Patient with Severe Obesity and Type 2 DiabetesAtypical Anorexia Nervosa Developed in a Patient with Severe Obesity and Type 2 Diabetes Following Sleeve Gastrectomy and Postoperative Treatment with Semaglutide and Tirzepatide.

Article

1 week ago • Therapeutic advances in endocrinology and metabolism

Use of GLP-1 Medicines in Primary Care: Preparedness, Fair Access, and the Risk of Unequal Obesity TreatmentGLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape.

🎖️ Top 10% JournalArticle

6 days ago • Frontiers in artificial intelligence

Using machine learning to predict blood sugar control and weight loss in people taking GLP-1 receptor drugsMachine learning algorithms for predicting glycemic control and weight loss outcomes in GLP-1 receptor agonist users.

📖 Top 20% JournalArticle

6 days ago • Journal of computer-aided molecular design

Creating a stable peptide drug that activates three hormone receptorsDesign of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity.

📖 Top 50% JournalArticle

6 days ago • Obesity (Silver Spring, Md.)

Testing oral GLP-1RA TERN-601 in adults with obesity or overweight: early phase placebo-controlled studies with increasing dosesOral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies.

🎖️ Top 10% JournalArticle

6 days ago • Lancet (London, England)

Effectiveness and safety of once-weekly injected zenagamtide, a new drug targeting blood sugar and appetite hormones, in type 2 diabetesEfficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

🥇 Top 1% JournalArticle